Prostate Cancer 2018

Prostate Cancer 2018 Banner


Date & Location
Saturday, April 28, 2018, 7:00 AM - 4:10 PM, Omni Shoreham Hotel, Washington, DC

Target Audience
Oncology, Radiation Oncology, Surgery, Urology

Overview

Online registration is now closed. 


If you have a question about your registration, please call us at (202) 780-1656 before 2:00 pm on Friday April 27, 2018. After 12pm on Friday April 27, 2018, you will need to register on-site. 

On-site registration will open at the Omni Shoreham Hotel, Washington, DC on Saturday April 28, at 7 AM. 

This multidisciplinary, one-day conference will provide a clinical update on the biology, therapeutic modalities, and surgical, medical and radiation-based management of patients with all stages of prostate cancer. There have been a number of recent advances in the diagnosis and treatment of patients with localized and metastatic prostate cancer. A respected panel of experts in the field will deliver state-of-the-art didactic lectures that will present the modern treatment approaches, recent and ongoing clinical trials, and future clinical practice directions. There will be a focus on the use of biomarkers and advanced imaging in the diagnosis and treatment of early stage prostate cancer as well as advances in the multidisciplinary management of patients with high-risk, locally advanced and metastatic prostate cancer. The application of new therapeutic agents, cutting edge radiation technology and evolving minimally invasive urologic surgical approaches will be extensively discussed. Information and regional resources for prostate cancer patients as well as treating physicians, nurses and trainees such as GUMDROP (Genitourinary Multidisciplinary DC Regional Oncology Project) and specialized centers of excellence will be shared.  The learning experience will be further enhanced through interactive audience participation, case presentations and panel discussions, and abundant opportunities for  individual audience members to interact with the faculty. The sessions will also cover broad topics of general interest moderated by  experts such as prostate cancer prevention, molecular biologic signatures, innovative approaches and health services research perspectives and their impact on current and future clinical practice. 



Objectives

After completing this activity, the participant will be able to;
  1. Interpret prostate MRIs in developing treatment strategies for organ-confined prostate cancer
  2. Interpret prostate biomarkers in planning treatment for organ-confined prostate cancer
  3. Recognize intermediate and high-risk patients who will benefit from brachytherapy
  4. Identify intermediate and high-risk patients who will benefit from immunotherapy
  5. Recognize intermediate and high-risk patients who will benefit from salvage therapy
  6. Distinguish the proper use of early chemohormonal therapy in patients with high-risk and metastatic prostate cancer
  7. Recognize intermediate and high-risk patients who will benefit from chemotherapy
  8. Recognize intermediate and high-risk patients who will benefit from testosterone replacement
  9. Illustrate the benefits of genetic testing for risk stratification in organ-confined prostate cancer
  10. Assess the latest guidelines of the National Comprehensive Cancer Network (NCCN)
  11. Examine the latest and current science and practices in the management of prostate cancer
  12. Identify the changes in medications and treatments for the different states of prostate cancer management
  13. Develop care plans for treatment and survivorship for prostate cancer patients to provide a continuum of care
  14. Compare the health risks, side effects, and symptoms related to brachytherapy, immunotherapy, salvage therapy, chemotherapy, and testosterone replacement.
  15. Analyze the difficulties and strategies for managing patients with the various stages of prostate cancer

Registration

Registration Fees:

  • Physician $150
  • Resident/Fellow $50
  • Advanced  Practice Clinician $75
  • Nurse $75
  • Allied Health $75
  • Industry $195


Accreditation

In support of improving patient care, MedStar Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

This activity was planned by and for the healthcare team, and learners will receive 7.25 Interprofessional Continuing Education (IPCE) credits for learning and change.